jcp conference-coverage

Conference Coverage

Bringing the Benefits of At-home Programs to Patients With Cancer Who Live in Rural Areas

06/09/2022

Researchers show how patients with cancer who are living in rural communities can receive the benefits of oncology hospital at home programs in a case study from the 2022 ASCO Annual Meeting.

Researchers show how patients...

06/09/2022

Journal of Clinical Pathways

Conference Coverage

Study Examines Charges Associated With US Hospital Payer-Specific Negotiated Mammography

06/09/2022

Robert Fee ;

A cross-sectional study of US acute care and critical access hospitals presented at the 2022 ASCO Annual Meeting examined the factors associated with payer-negotiated mammography charges.

A cross-sectional study of US...

06/09/2022

Journal of Clinical Pathways

Conference Coverage

Case Study Assesses Self-Reported Financial Difficulties Among Patients With Multiple Myeloma or Chronic Lymphocytic Leukemia

06/09/2022

Robert Fee ;

A study presented by the Alliance for Clinical Trials in Oncology at the 2022 ASCO Annual Meeting confirms that many patients with blood cancers experience financial difficulties.

A study presented by the...

06/09/2022

Journal of Clinical Pathways

Conference Coverage

Factors Predicting the Likelihood of Undergoing Biomarker Testing in Ovarian Cancer

06/08/2022

Marta Rybczynski ;

According to findings presented at ASCO 2022, only 55% of patients with ovarian cancer underwent biomarker testing due to factors such as insurance type, ECOG status, and region.

According to findings presented...

06/08/2022

Journal of Clinical Pathways

Conference Coverage

Apatinib Safe, Effective for the Treatment of Advanced Platinum-Resistant Recurrent Epithelial Ovarian Cancer

06/08/2022

Marta Rybczynski ;

Apatinib therapy may be effective among patients with advanced platinum-resistant relapsed epithelial ovarian cancer, with manageable toxicities, according to a study presented at ASCO 2022.

Apatinib therapy may be...

06/08/2022

Journal of Clinical Pathways

Conference Coverage

Understanding Oncologists’ Attitudes on Communicating With Patients About the Cost of Cancer

06/08/2022

Amber Denham ;

According to data from an online survey summarized at the 2022 ASCO Annual Meeting, despite believing cost of cancer care should be discussed in the clinic, most hematologists/oncologists surveyed did not do so.

According to data from an online...

06/08/2022

Journal of Clinical Pathways

Conference Coverage

Real-world Treatment Patterns for Patients With Metastatic Castration-Resistant Prostate Cancer

06/06/2022

Robert Fee ;

Although numerous treatments with different mechanisms of action are approved for metastatic castration-resistant prostate cancer (mCRPC), the sequencing for management of these patients has been evolving post availability of trials.

Although numerous treatments...

06/06/2022

Journal of Clinical Pathways

Conference Coverage

The Financial Impact of Biosimilar Adoption in the Oncology Care Model

06/05/2022

Robert Fee ;

In a study presented at the 2022 ASCO Annual Meeting, researchers examined the utilization and the financial impact of biosimilar adoption in The US Oncology Network Over a six-month period.

In a study presented at the 2022...

06/05/2022

Journal of Clinical Pathways

Conference Coverage

Real-World Survival Outcomes With PARP Inhibitor Maintenance in Advanced Ovarian Cancer

06/05/2022

Robert Fee ;

Study examines patient records over five years to determine real-world efficacy benefits of PARPi therapy vs active surveillance confirms the efficacy benefits that have been demonstrated in randomized clinical trials of PARPis vs placebo.

Study examines patient records...

06/05/2022

Journal of Clinical Pathways

Conference Coverage

Bevacizumab-awwb Safe, Effective Among Patients With Metastatic Colorectal Cancer

06/04/2022

Robert Fee ;

Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.

Study examines real-world...

06/04/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update: Impact on NSCLC Landscape

11/15/2024

The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products